Gemcitabine 1 g Powder for Solution for Infusion
Sponsors
Bristol-Myers Squibb International Corporation, Bristol Myers Squibb International Corporation, SOTIO Biotech a.s., Maia Biotechnology Inc.
Conditions
Early Stage Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerUntreated Unresectable or Metastatic Urothelial Cancergastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction (GEJ) and pancreatic adenocarcinoma
Phase 1
Phase 3
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet
Chemotherapy in Early Stage NSCLC
CompletedCTIS2022-501360-18-00
Start: 2017-03-15End: 2024-12-03Target: 194Updated: 2024-12-03
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Active, not recruitingCTIS2022-501784-40-00
Start: 2017-05-26Target: 701Updated: 2026-01-26
A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-agent Chemotherapy as Third-line Treatment in Subjects with Advanced / Metastatic Non-Small Cell Lung Cancer (NSCLC)
Not yet recruitingCTIS2024-520164-33-00
Target: 80Updated: 2025-09-19